Deaths from chronic heart failure was reduced by 20 percent when compared to an existing treatment, with an experimental drug from Swiss pharma giant Novartis, reveals the results of a vast new study. The new drug, called LCZ696, has been labelled a potential "blockbuster" with sales in the billions of dollars, say analysts. Cardiovascular failure, in which the heart does not pump blood effectively, kills at least 26 million people a year worldwide. ...
Read More
No comments:
Post a Comment